Lupus Nephritis

Renal arteriosclerosis is both accelerated and premature among patients with lupus nephritis by 2 decades, compared with healthy peers, according to data published in Arthritis Care & Research.

Phase 3 results from the AURORA study demonstrated combining voclosporin with mycophenolate and low-dose corticosteroids was superior to standard care for treating patients with lupus nephritis. The results were made available through a press release from Aurinia Pharmaceuticals.

ATLANTA — Limited access to supportive laboratory assays in developing countries significantly reduces the diagnostic utility of the ACR/EULAR criteria for systemic lupus erythematosus, which relies on an antinuclear antibody titer of 1:80 for its entry criterion, noted a presenter at the 2019 ACR/ARP Annual Meeting.

WASHINGTON — Researchers of a poster presented at ASN Kidney Week observed wide fluctuations in serum creatinine in patients with lupus nephritis in remission.

WASHINGTON — At ASN Kidney Week, Brad H. Rovin, MD, presented results of the NOBILITY trial, a phase 2 randomized, controlled study of obinutuzumab with mycophenolate and corticosteroids in patients with proliferative lupus nephritis.

SAN DIEGO — Rheumatologists treating patients with lupus nephritis should make a concerted effort to reduce or avoid use of NSAIDs and other nephrotoxic drugs in order to improve long-term outcomes, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

The FDA has granted Gazyva breakthrough therapy designation for the treatment of adult patients with lupus nephritis, according to a Genentech press release.

Following positive results from phase 2 of the NOBILITY study, the FDA has granted breakthrough therapy designation to Genentech’s Gazyva for lupus nephritis.